| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/13/2015 | US8932584 Solubilized CoQ-10 |
| 01/13/2015 | US8932579 Biological effects of compositions comprising rosmarinic acid |
| 01/13/2015 | US8932572 Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
| 01/13/2015 | US8932571 Skin care product |
| 01/13/2015 | US8932567 Method of enhancing hair growth |
| 01/13/2015 | US8932561 Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| 01/13/2015 | CA2812970C Heterocyclyl compounds as histamine h3 receptor ligands |
| 01/13/2015 | CA2804173C Sulfonamide nav1.7 inhibitors |
| 01/13/2015 | CA2780533C 5-hydroxypyrimidine-4-carboxamide derivative |
| 01/13/2015 | CA2747395C Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
| 01/13/2015 | CA2741041C Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative |
| 01/13/2015 | CA2741038C Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate |
| 01/13/2015 | CA2740200C Methods and compositions for treating dermatological diseases and conditions |
| 01/13/2015 | CA2737355C Rapalogs, pharmaceutical compositions, preparation methods and uses thereof |
| 01/13/2015 | CA2730930C Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| 01/13/2015 | CA2681030C Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
| 01/13/2015 | CA2679175C Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
| 01/13/2015 | CA2676981C Powders for reconstitution |
| 01/13/2015 | CA2670858C Salts of 3-(3-amino-2-(r)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one |
| 01/13/2015 | CA2669230C Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof |
| 01/13/2015 | CA2669187C Bicyclic heterocycles, drugs containing said compounds, the use thereof and methods for preparing same |
| 01/13/2015 | CA2668923C Use of tri-substituted glycerol compounds for the treatment of radiation injuries |
| 01/13/2015 | CA2666837C Arylsulfonamide compounds |
| 01/13/2015 | CA2660520C Hepatitis c virus inhibitors |
| 01/13/2015 | CA2654798C Flibanserin for the treatment of urinary incontinence and related diseases |
| 01/13/2015 | CA2632690C Rnai-mediated inhibition of igf1r for treatment of ocular angiogenesis |
| 01/13/2015 | CA2596759C Local treatment of neurofibromas |
| 01/13/2015 | CA2580730C Tetrahydroindolone derivatives for treatment of neurological conditions |
| 01/13/2015 | CA2521402C Pectate lyases, nucleic acids encoding them and methods for making and using them |
| 01/13/2015 | CA2508065C Antiproliferative drug and delivery device |
| 01/13/2015 | CA2498777C Non-sequence complementary antiviral oligonucleotides |
| 01/13/2015 | CA2457282C Method for expression of small antiviral rna molecules within a cell |
| 01/13/2015 | CA2436469C Composition for heart disease, method to prepare same and uses thereof |
| 01/13/2015 | CA2426601C Cyanoguanidine prodrugs |
| 01/08/2015 | WO2015003166A1 Substituted benzofuranyl and benzoxazolyl compounds and uses thereof |
| 01/08/2015 | WO2015003164A1 Coq10 (ubiquinone, ubiquinol), vitamin a (retinoic acid, retinol), vitamin e (tocotrienol, tocopherol) and methods of use |
| 01/08/2015 | WO2015003146A1 Boronic acid derivatives of resveratrol for activating deacetylase enzymes |
| 01/08/2015 | WO2015003131A1 Substituted purine compounds |
| 01/08/2015 | WO2015003128A1 Reducing adverse side effects of a compound by a neurotoxin |
| 01/08/2015 | WO2015003113A2 Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded rna |
| 01/08/2015 | WO2015003109A1 Capsule formulation comprising fexofenadine |
| 01/08/2015 | WO2015003095A1 Sunless tanning compounds and compositions |
| 01/08/2015 | WO2015003083A1 Compounds for treatment of cystic fibrosis |
| 01/08/2015 | WO2015003059A1 Methods and compositions for deterring abuse |
| 01/08/2015 | WO2015003030A1 Method of treating neurodegenerative disorders |
| 01/08/2015 | WO2015003025A1 NOVEL FORMULATIONS OF FACTOR VIIa INHIBITORS AND UTILITY |
| 01/08/2015 | WO2015003021A2 Dietary supplements and composition for treating cancer |
| 01/08/2015 | WO2015003003A1 Ship inhibition to combat obesity |
| 01/08/2015 | WO2015003002A1 Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| 01/08/2015 | WO2015002996A1 Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy |
| 01/08/2015 | WO2015002994A2 Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
| 01/08/2015 | WO2015002952A1 Methods for treating hcv |
| 01/08/2015 | WO2015002926A1 Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
| 01/08/2015 | WO2015002918A1 Ido inhibitors |
| 01/08/2015 | WO2015002915A1 Tricyclic pyri do-carboxam i d e derivatives as rock inhibitors |
| 01/08/2015 | WO2015002894A1 Purinone compounds as kinase inhibitors |
| 01/08/2015 | WO2015002861A1 Transfection of mesothelium body cavity lining with gene agents prior to chemotherapy to treat cancer |
| 01/08/2015 | WO2015002818A1 Treating or preventing nephrogenic diabetes insipidus |
| 01/08/2015 | WO2015002786A1 Antimicrobial foams and methods of making same |
| 01/08/2015 | WO2015002766A1 Anti-tumor therapy |
| 01/08/2015 | WO2015002755A2 Compounds for the treatment of malaria |
| 01/08/2015 | WO2015002754A2 Novel bicyclic bromodomain inhibitors |
| 01/08/2015 | WO2015002576A1 Application of adsorbed drone brood homogenate and of vitamin d3 or d-group vitamins and/or active metabolites thereof for preventing and treating viral diseases |
| 01/08/2015 | WO2015002569A1 Method for immobilizing therapeutic drugs on the surface of detonation nanodiamonds |
| 01/08/2015 | WO2015002537A1 Amino acid composition for use in the treatment of a pdd |
| 01/08/2015 | WO2015002527A1 Amino acid composition for use in the treatment of a pdd |
| 01/08/2015 | WO2015002450A1 Pharmaceutical composition for preventing or treating cognitive impairment or concentration impairment disorders, comprising eclalbasaponin or derivative thereof |
| 01/08/2015 | WO2015002434A1 Novel tenofovir disoproxil salt and the preparation method thereof |
| 01/08/2015 | WO2015002393A1 Composition for treating or preventing inflammatory skin disease, comprising, as active ingredient, immature citrus fruit extract, or synephrine or salt thereof |
| 01/08/2015 | WO2015002391A1 Composition having a function for alleviating premenstrual syndrome and menstrual pain |
| 01/08/2015 | WO2015002347A1 Liquid-phase antioxidant composition comprising kalanchoe extract for after-treatment following photodynamic therapy |
| 01/08/2015 | WO2015002293A1 Wnt SIGNAL INHIBITOR |
| 01/08/2015 | WO2015002264A1 Method for preventing and/or treating digital dermatitis |
| 01/08/2015 | WO2015002239A1 Oral ultraviolet resistance enhancer |
| 01/08/2015 | WO2015002231A1 Heterocyclic compound |
| 01/08/2015 | WO2015002230A1 Amide compound |
| 01/08/2015 | WO2015002211A1 Fused heterocyclic compound and pest control use thereof |
| 01/08/2015 | WO2015002150A1 Novel compound, organic cation transporter 3 detection agent, and organic cation transporter 3 activity inhibitor |
| 01/08/2015 | WO2015002119A1 Pyrazole-alcohol compound and pharmaceutical application therefor |
| 01/08/2015 | WO2015002118A1 Fluorene-amide compound and pharmaceutical application therefor |
| 01/08/2015 | WO2015002095A1 Irritation relieving agent |
| 01/08/2015 | WO2015002091A1 Water-soluble hyaluronic acid gel and method for producing same |
| 01/08/2015 | WO2015002078A1 Novel boronic acid compound preparation |
| 01/08/2015 | WO2015002061A1 Phenylimidazole derivative, and therapeutic medicine or preventive medicine for inflammatory disease, etc. |
| 01/08/2015 | WO2015001995A1 Rocuronium preparation with improved vascular pain, method for producing same, and method for suppressing and relieving vascular pain using same |
| 01/08/2015 | WO2015001891A1 Composition for promoting collagen production, for promoting elastin production, and/or for promoting keratinocyte migration, and usage therefor |
| 01/08/2015 | WO2015001890A1 Composition for suppressing adipocyte differentiation, for reducing fat accumulation, and/or for promoting adiponectin secretion and usage for said composition |
| 01/08/2015 | WO2015001799A1 Therapeutic agent and prophylactic agent for babesiosis |
| 01/08/2015 | WO2015001573A1 Synergistic compositions |
| 01/08/2015 | WO2015001570A1 Rnai agent for inhibition of chikungunya virus |
| 01/08/2015 | WO2015001569A1 A solid pharmaceutical composition of ivabradine for oral administration |
| 01/08/2015 | WO2015001568A2 Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof |
| 01/08/2015 | WO2015001567A1 Process for the preparation of (s)-4-[(3-chloro-4-methoxybenzyl)amino]-2-[2- (hydroxymethyl)-1-pyrrolidinyl]-n-(2-pyrimidinyl methyl-5-pyrimidine carboxamide |
| 01/08/2015 | WO2015001565A2 "an improved process for the preparation of 3-aryloxy-3- phenylpropylamine and salt thereof" |
| 01/08/2015 | WO2015001532A1 Inhibition of the synthesis of beta-app or of the activity of the a‑beta peptide in the choroid plexus |
| 01/08/2015 | WO2015001518A1 Bicyclic compounds useful for treating diseases caused by retroviruses |
| 01/08/2015 | WO2015001491A1 Pi3k protein kinase inhibitors, particularly delta and/or gamma inhibitors |
| 01/08/2015 | WO2015001489A1 Pharmaceutical compositions of ticagrelor |
| 01/08/2015 | WO2015001488A1 Extended-release tablets of paliperidone and processes of preparation thereof |
| 01/08/2015 | WO2015001478A1 Liquid pharmaceutical composition for oral administration comprising fexofenadine |